Ofranergene obadenovec

Drug Profile

Ofranergene obadenovec

Alternative Names: GT-111; VB 111

Latest Information Update: 12 Jan 2017

Price : $50

At a glance

  • Originator Vascular Biogenics
  • Developer Dana-Farber Cancer Institute; Massachusetts General Hospital; VBL Therapeutics
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Angiogenesis modulating agents; Gene expression modulators; Vascular disrupting agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Ovarian cancer; Thyroid cancer
  • No development reported Lung cancer

Most Recent Events

  • 11 Jan 2017 Ofranergene obadenovec is available for licensing as of 09 Jan 2017. http://www.vblrx.com/
  • 09 Jan 2017 VBL Therapeutics completes enrolment in the phase III GLOBE trial for Glioblastoma in USA, Canada and Israel
  • 05 Dec 2016 Efficacy data from a phase II trial in Ovarian cancer released by VBL Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top